Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors: Optimization of Whole-Cell Anticryptococcal Activity and Insights into the Structural Origins of Cryptococcal Selectivity

Marcyk, P; LeBlanc, E.; Kuntz, D.; Xue, A.; Ortiz, F.; Trilles, R.; Bengtson, S.; Kenney, T.; Huang, D.; Robbins, N.; Williams, N.; Krysan, D.; Privé, G.; Whitesell, L.; Cowen, L.; Brown, L.

doi:10.1021/acs.jmedchem.0c01777

Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors: Optimization of Whole-Cell Anticryptococcal Activity and Insights into the Structural Origins of Cryptococcal Selectivity

Journal Article · 01 January 2022 · Journal of Medicinal Chemistry

DOI:https://doi.org/10.1021/acs.jmedchem.0c01777· OSTI ID:1783758

Marcyk, P; LeBlanc, E.; Kuntz, D.; Xue, A.; Ortiz, F.; Trilles, R.; Bengtson, S.; Kenney, T.; Huang, D.; Robbins, N.; Williams, N.; Krysan, D.; Privé, G.; Whitesell, L.; Cowen, L.; Brown, L.

Research Organization:: Brookhaven National Lab. (BNL), Upton, NY (United States)

Sponsoring Organization:: ~OTHER

DOE Contract Number:: SC0012704

OSTI ID:: 1783758

Report Number(s):: BNL-221440-2021-JACI

Journal Information:: Journal of Medicinal Chemistry, Vol. 64, Issue 2

Country of Publication:: United States

Language:: English

References (86)

Hidden Killers: Human Fungal Infections Brown, G. D.; Denning, D. W.; Gow, N. A. R. Science Translational Medicine, Vol. 4, Issue 165 https://doi.org/10.1126/scitranslmed.3004404	journal	December 2012
Worldwide emergence of resistance to antifungal drugs challenges human health and food security Fisher, Matthew C.; Hawkins, Nichola J.; Sanglard, Dominique Science, Vol. 360, Issue 6390 https://doi.org/10.1126/science.aap7999	journal	May 2018
Tackling Human Fungal Infections Brown, G. D.; Denning, D. W.; Levitz, S. M. Science, Vol. 336, Issue 6082 https://doi.org/10.1126/science.1222236	journal	May 2012
Epidemiology of Invasive Mycoses in North America Pfaller, Michael A.; Diekema, Daniel J. Critical Reviews in Microbiology, Vol. 36, Issue 1 https://doi.org/10.3109/10408410903241444	journal	January 2010
Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS Park, Benjamin J.; Wannemuehler, Kathleen A.; Marston, Barbara J. AIDS, Vol. 23, Issue 4 https://doi.org/10.1097/QAD.0b013e328322ffac	journal	January 2009
Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis Rajasingham, Radha; Smith, Rachel M.; Park, Benjamin J. The Lancet Infectious Diseases, Vol. 17, Issue 8 https://doi.org/10.1016/S1473-3099(17)30243-8	journal	August 2017
Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries Loyse, Angela; Burry, Jessica; Cohn, Jennifer The Lancet Infectious Diseases, Vol. 19, Issue 4 https://doi.org/10.1016/S1473-3099(18)30493-6	journal	April 2019
History of the development of azole derivatives Maertens, J. A. Clinical Microbiology and Infection, Vol. 10 https://doi.org/10.1111/j.1470-9465.2004.00841.x	journal	January 2004
Amphotericin forms an extramembranous and fungicidal sterol sponge Anderson, Thomas M.; Clay, Mary C.; Cioffi, Alexander G. Nature Chemical Biology, Vol. 10, Issue 5 https://doi.org/10.1038/nchembio.1496	journal	March 2014
Stress, Drugs, and Evolution: the Role of Cellular Signaling in Fungal Drug Resistance Cowen, Leah E.; Steinbach, William J. Eukaryotic Cell, Vol. 7, Issue 5 https://doi.org/10.1128/EC.00041-08	journal	May 2008
Regulatory Circuitry Governing Fungal Development, Drug Resistance, and Disease Shapiro, Rebecca S.; Robbins, Nicole; Cowen, Leah E. Microbiology and Molecular Biology Reviews, Vol. 75, Issue 2 https://doi.org/10.1128/MMBR.00045-10	journal	June 2011
Functional Genomic Screening Reveals Core Modulators of Echinocandin Stress Responses in Candida albicans Caplan, Tavia; Polvi, Elizabeth J.; Xie, Jinglin L. Cell Reports, Vol. 23, Issue 8 https://doi.org/10.1016/j.celrep.2018.04.084	journal	May 2018
Molecular Evolution of Antifungal Drug Resistance Robbins, Nicole; Caplan, Tavia; Cowen, Leah E. Annual Review of Microbiology, Vol. 71, Issue 1 https://doi.org/10.1146/annurev-micro-030117-020345	journal	September 2017
Mapping the Hsp90 Genetic Network Reveals Ergosterol Biosynthesis and Phosphatidylinositol-4-Kinase Signaling as Core Circuitry Governing Cellular Stress O’Meara, Teresa R.; Veri, Amanda O.; Polvi, Elizabeth J. PLOS Genetics, Vol. 12, Issue 6 https://doi.org/10.1371/journal.pgen.1006142	journal	June 2016
Genetic Analysis of Candida auris Implicates Hsp90 in Morphogenesis and Azole Tolerance and Cdr1 in Azole Resistance Kim, Sang Hu; Iyer, Kali R.; Pardeshi, Lakhansing mBio, Vol. 10, Issue 1 https://doi.org/10.1128/mBio.02529-18	journal	February 2019
Tuning Hsf1 levels drives distinct fungal morphogenetic programs with depletion impairing Hsp90 function and overexpression expanding the target space Veri, Amanda O.; Miao, Zhengqiang; Shapiro, Rebecca S. PLOS Genetics, Vol. 14, Issue 3 https://doi.org/10.1371/journal.pgen.1007270	journal	March 2018
The Hsp90 Chaperone Network Modulates Candida Virulence Traits O’Meara, Teresa R.; Robbins, Nicole; Cowen, Leah E. Trends in Microbiology, Vol. 25, Issue 10 https://doi.org/10.1016/j.tim.2017.05.003	journal	October 2017
Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs Leach, Michelle D.; Klipp, Edda; Cowen, Leah E. Nature Reviews Microbiology, Vol. 10, Issue 10 https://doi.org/10.1038/nrmicro2875	journal	September 2012
Hsp90 Potentiates the Rapid Evolution of New Traits: Drug Resistance in Diverse Fungi Cowen, L. E. Science, Vol. 309, Issue 5744 https://doi.org/10.1126/science.1118370	journal	September 2005
Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin Singh, Sheena D.; Robbins, Nicole; Zaas, Aimee K. PLoS Pathogens, Vol. 5, Issue 7 https://doi.org/10.1371/journal.ppat.1000532	journal	July 2009
Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease Cowen, Leah E.; Singh, Sheena D.; Köhler, Julia R. Proceedings of the National Academy of Sciences, Vol. 106, Issue 8 https://doi.org/10.1073/pnas.0813394106	journal	February 2009
Heat shock protein 90 localizes to the surface and augments virulence factors of Cryptococcus neoformans Chatterjee, Sharanya; Tatu, Utpal PLOS Neglected Tropical Diseases, Vol. 11, Issue 8 https://doi.org/10.1371/journal.pntd.0005836	journal	August 2017
Inhibition of heat-shock protein 90 enhances the susceptibility to antifungals and reduces the virulence of Cryptococcus neoformans/Cryptococcus gattii species complex Cordeiro, Rossana de Aguiar; Evangelista, Antonio José de Jesus; Serpa, Rosana Microbiology, Vol. 162, Issue 2 https://doi.org/10.1099/mic.0.000222	journal	February 2016
Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions Li, Li; Wang, Lei; You, Qi-Dong Journal of Medicinal Chemistry, Vol. 63, Issue 5 https://doi.org/10.1021/acs.jmedchem.9b00940	journal	October 2019
Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation Jaeger, Alex M.; Stopfer, Lauren; Lee, Sunmin Clinical Cancer Research, Vol. 25, Issue 21 https://doi.org/10.1158/1078-0432.CCR-19-0596	journal	June 2019
HSP90: Enabler of Cancer Adaptation Jaeger, Alex M.; Whitesell, Luke Annual Review of Cancer Biology, Vol. 3, Issue 1 https://doi.org/10.1146/annurev-cancerbio-030518-055533	journal	March 2019
Paralog Specific Hsp90 Inhibitors - A Brief History and a Bright Future T. Gewirth, Daniel Current Topics in Medicinal Chemistry, Vol. 16, Issue 25 https://doi.org/10.2174/1568026616666160413141154	journal	August 2016
Development of a Mitochondria-Targeted Hsp90 Inhibitor Based on the Crystal Structures of Human TRAP1 Lee, Changwook; Park, Hye-Kyung; Jeong, Hanbin Journal of the American Chemical Society, Vol. 137, Issue 13 https://doi.org/10.1021/ja511893n	journal	March 2015
Development of Glucose Regulated Protein 94-Selective Inhibitors Based on the BnIm and Radamide Scaffold Crowley, Vincent M.; Khandelwal, Anuj; Mishra, Sanket Journal of Medicinal Chemistry, Vol. 59, Issue 7 https://doi.org/10.1021/acs.jmedchem.6b00085	journal	March 2016
Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2 Patel, Pallav D.; Yan, Pengrong; Seidler, Paul M. Nature Chemical Biology, Vol. 9, Issue 11 https://doi.org/10.1038/nchembio.1335	journal	September 2013
Structure Based Design of a Grp94-Selective Inhibitor: Exploiting a Key Residue in Grp94 To Optimize Paralog-Selective Binding Que, Nanette L. S.; Crowley, Vincent M.; Duerfeldt, Adam S. Journal of Medicinal Chemistry, Vol. 61, Issue 7 https://doi.org/10.1021/acs.jmedchem.7b01608	journal	March 2018
Exploiting the interaction between Grp94 and aggregated myocilin to treat glaucoma Stothert, Andrew R.; Suntharalingam, Amirthaa; Huard, Dustin J. E. Human Molecular Genetics, Vol. 23, Issue 24 https://doi.org/10.1093/hmg/ddu367	journal	July 2014
Isoform-selective Hsp90 inhibition rescues model of hereditary open-angle glaucoma Stothert, Andrew R.; Suntharalingam, Amirthaa; Tang, Xiaolan Scientific Reports, Vol. 7, Issue 1 https://doi.org/10.1038/s41598-017-18344-4	journal	December 2017
Development of radamide analogs as Grp94 inhibitors Muth, Aaron; Crowley, Vincent; Khandelwal, Anuj Bioorganic & Medicinal Chemistry, Vol. 22, Issue 15 https://doi.org/10.1016/j.bmc.2014.05.075	journal	August 2014
Resorcinol-Based Grp94-Selective Inhibitors Khandelwal, Anuj; Crowley, Vincent M.; Blagg, Brian S. J. ACS Medicinal Chemistry Letters, Vol. 8, Issue 10 https://doi.org/10.1021/acsmedchemlett.7b00193	journal	September 2017
Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor Khandelwal, Anuj; Kent, Caitlin N.; Balch, Maurie Nature Communications, Vol. 9, Issue 1 https://doi.org/10.1038/s41467-017-02013-1	journal	January 2018
TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90 and , Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models Ohkubo, S.; Kodama, Y.; Muraoka, H. Molecular Cancer Therapeutics, Vol. 14, Issue 1 https://doi.org/10.1158/1535-7163.MCT-14-0219	journal	November 2014
Identification of Novel HSP90α/β Isoform Selective Inhibitors Using Structure-Based Drug Design. Demonstration of Potential Utility in Treating CNS Disorders such as Huntington’s Disease Ernst, Justin T.; Neubert, Timothy; Liu, Michael Journal of Medicinal Chemistry, Vol. 57, Issue 8 https://doi.org/10.1021/jm500042s	journal	April 2014
Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity—Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases Ernst, Justin T.; Liu, Michael; Zuccola, Harmon Bioorganic & Medicinal Chemistry Letters, Vol. 24, Issue 1 https://doi.org/10.1016/j.bmcl.2013.11.036	journal	January 2014
Structural basis for species-selective targeting of Hsp90 in a pathogenic fungus Whitesell, Luke; Robbins, Nicole; Huang, David S. Nature Communications, Vol. 10, Issue 1 https://doi.org/10.1038/s41467-018-08248-w	journal	January 2019
Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design Woodhead, Andrew J.; Angove, Hayley; Carr, Maria G. Journal of Medicinal Chemistry, Vol. 53, Issue 16 https://doi.org/10.1021/jm100060b	journal	August 2010
Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors Do, Khanh; Speranza, Giovanna; Chang, Lun-Ching Investigational New Drugs, Vol. 33, Issue 4 https://doi.org/10.1007/s10637-015-0255-1	journal	June 2015
Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour Wagner, Andrew J.; Agulnik, Mark; Heinrich, Michael C. European Journal of Cancer, Vol. 61 https://doi.org/10.1016/j.ejca.2016.03.076	journal	July 2016
Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas Canella, Alessandro; Welker, Alessandra M.; Yoo, Ji Young Clinical Cancer Research, Vol. 23, Issue 20 https://doi.org/10.1158/1078-0432.CCR-16-3151	journal	July 2017
Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma Stühmer, T.; Zöllinger, A.; Siegmund, D. Leukemia, Vol. 22, Issue 8 https://doi.org/10.1038/leu.2008.111	journal	May 2008
NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models Jensen, Michael Rugaard; Schoepfer, Joseph; Radimerski, Thomas Breast Cancer Research, Vol. 10, Issue 2 https://doi.org/10.1186/bcr1996	journal	April 2008
Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors Doi, Toshihiko; Onozawa, Yusuke; Fuse, Nozomu Cancer Chemotherapy and Pharmacology, Vol. 74, Issue 3 https://doi.org/10.1007/s00280-014-2521-x	journal	July 2014
Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma: Phase 1/1B Trial of NVP-AUY922 in MM Seggewiss-Bernhardt, Ruth; Bargou, Ralf C.; Goh, Yeow Tee Cancer, Vol. 121, Issue 13 https://doi.org/10.1002/cncr.29339	journal	March 2015
A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer Renouf, D. J.; Hedley, D.; Krzyzanowska, M. K. Cancer Chemotherapy and Pharmacology, Vol. 78, Issue 3 https://doi.org/10.1007/s00280-016-3102-y	journal	July 2016
A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors Bendell, Johanna C.; Bauer, Todd M.; Lamar, Ruth Cancer Investigation, Vol. 34, Issue 6 https://doi.org/10.1080/07357907.2016.1193746	journal	June 2016
The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors Lin, Tzu-Yin; Bear, Misty; Du, Zhenjian Experimental Hematology, Vol. 36, Issue 10 https://doi.org/10.1016/j.exphem.2008.05.001	journal	October 2008
Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy Ying, Weiwen; Du, Zhenjian; Sun, Lijun Molecular Cancer Therapeutics, Vol. 11, Issue 2 https://doi.org/10.1158/1535-7163.MCT-11-0755	journal	December 2011
Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program: Ganetespib Pediatric Preclinical Testing Lock, Richard B.; Carol, Hernan; Maris, John M. Pediatric Blood & Cancer, Vol. 60, Issue 7 https://doi.org/10.1002/pbc.24451	journal	January 2013
A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer Jhaveri, Komal; Chandarlapaty, Sarat; Lake, Diana Clinical Breast Cancer, Vol. 14, Issue 3 https://doi.org/10.1016/j.clbc.2013.12.012	journal	June 2014
A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer Jhaveri, Komal; Wang, Rui; Teplinsky, Eleonora Breast Cancer Research, Vol. 19, Issue 1 https://doi.org/10.1186/s13058-017-0879-5	journal	August 2017
A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study Thakur, Manish K.; Heilbrun, Lance K.; Sheng, Shijie Investigational New Drugs, Vol. 34, Issue 1 https://doi.org/10.1007/s10637-015-0307-6	journal	November 2015
A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma Goyal, Lipika; Wadlow, Raymond C.; Blaszkowsky, Lawrence S. Investigational New Drugs, Vol. 33, Issue 1 https://doi.org/10.1007/s10637-014-0164-8	journal	September 2014
A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non–Small Cell Lung Cancer Socinski, Mark A.; Goldman, Jonathan; El-Hariry, Iman Clinical Cancer Research, Vol. 19, Issue 11 https://doi.org/10.1158/1078-0432.CCR-12-3381	journal	April 2013
A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies Goldman, Jonathan W.; Raju, Robert N.; Gordon, Gregory A. BMC Cancer, Vol. 13, Issue 1 https://doi.org/10.1186/1471-2407-13-152	journal	March 2013
Design and Synthesis of Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors Huang, David S.; LeBlanc, Emmanuelle V.; Shekhar-Guturja, Tanvi Journal of Medicinal Chemistry, Vol. 63, Issue 5 https://doi.org/10.1021/acs.jmedchem.9b00826	journal	September 2019
Susceptibility of Cryptococcus neoformans Biofilms to Antifungal Agents In Vitro Martinez, Luis R.; Casadevall, Arturo Antimicrobial Agents and Chemotherapy, Vol. 50, Issue 3 https://doi.org/10.1128/AAC.50.3.1021-1033.2006	journal	March 2006
Vesicular transport across the fungal cell wall Casadevall, Arturo; Nosanchuk, Joshua D.; Williamson, Peter Trends in Microbiology, Vol. 17, Issue 4 https://doi.org/10.1016/j.tim.2008.12.005	journal	April 2009
Multiple Disguises for the Same Party: The Concepts of Morphogenesis and Phenotypic Variations in Cryptococcus neoformans? Zaragoza, Oscar Frontiers in Microbiology, Vol. 2 https://doi.org/10.3389/fmicb.2011.00181	journal	January 2011
The Cryptococcus neoformans Capsule: a Sword and a Shield O'Meara, T. R.; Alspaugh, J. A. Clinical Microbiology Reviews, Vol. 25, Issue 3 https://doi.org/10.1128/CMR.00001-12	journal	July 2012
Efflux-Mediated Antifungal Drug Resistance Cannon, Richard D.; Lamping, Erwin; Holmes, Ann R. Clinical Microbiology Reviews, Vol. 22, Issue 2 https://doi.org/10.1128/CMR.00051-08	journal	April 2009
Analysis of protein-ligand interactions by fluorescence polarization Rossi, Ana M.; Taylor, Colin W. Nature Protocols, Vol. 6, Issue 3 https://doi.org/10.1038/nprot.2011.305	journal	March 2011
An Automated Liquid Chromatography-Mass Spectrometry Process to Determine Metabolic Stability Half-Life and Intrinsic Clearance of Drug Candidates by Substrate Depletion McNaney, Colleen A.; Drexler, Dieter M.; Hnatyshyn, Serhiy Y. ASSAY and Drug Development Technologies, Vol. 6, Issue 1 https://doi.org/10.1089/adt.2007.103	journal	February 2008
A Repurposing Approach Identifies Off-Patent Drugs with Fungicidal Cryptococcal Activity, a Common Structural Chemotype, and Pharmacological Properties Relevant to the Treatment of Cryptococcosis Butts, Arielle; DiDone, Louis; Koselny, Kristy Eukaryotic Cell, Vol. 12, Issue 2 https://doi.org/10.1128/EC.00314-12	journal	December 2012
4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer Brough, Paul A.; Aherne, Wynne; Barril, Xavier Journal of Medicinal Chemistry, Vol. 51, Issue 2 https://doi.org/10.1021/jm701018h	journal	January 2008
Purine-Scaffold Hsp90 Inhibitors Taldone, Tony; Chiosis, Gabriela Current Topics in Medicinal Chemistry, Vol. 9, Issue 15 https://doi.org/10.2174/156802609789895737	journal	November 2009
Crystal Structure of an Hsp90–Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent Stebbins, Charles E.; Russo, Alicia A.; Schneider, Christine Cell, Vol. 89, Issue 2 https://doi.org/10.1016/S0092-8674(00)80203-2	journal	April 1997
The alpha aneurism: a structural motif revealed in an insertion mutant of staphylococcal nuclease. Keefe, L. J.; Sondek, J.; Shortle, D. Proceedings of the National Academy of Sciences, Vol. 90, Issue 8 https://doi.org/10.1073/pnas.90.8.3275	journal	April 1993
Structure-Activity Relationships in Purine-Based Inhibitor Binding to HSP90 Isoforms Wright, Lisa; Barril, Xavier; Dymock, Brian Chemistry & Biology, Vol. 11, Issue 6 https://doi.org/10.1016/j.chembiol.2004.03.033	journal	June 2004
Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy Friesner, Richard A.; Banks, Jay L.; Murphy, Robert B. Journal of Medicinal Chemistry, Vol. 47, Issue 7 https://doi.org/10.1021/jm0306430	journal	March 2004
Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening Halgren, Thomas A.; Murphy, Robert B.; Friesner, Richard A. Journal of Medicinal Chemistry, Vol. 47, Issue 7 https://doi.org/10.1021/jm030644s	journal	March 2004
Structure-Based Drug Design: Exploring the Proper Filling of Apolar Pockets at Enzyme Active Sites Zürcher, Martina; Diederich, François The Journal of Organic Chemistry, Vol. 73, Issue 12 https://doi.org/10.1021/jo800527n	journal	June 2008
A Medicinal Chemist’s Guide to Molecular Interactions Bissantz, Caterina; Kuhn, Bernd; Stahl, Martin Journal of Medicinal Chemistry, Vol. 53, Issue 14 https://doi.org/10.1021/jm100112j	journal	July 2010
Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide. Granger, D. L.; Perfect, J. R.; Durack, D. T. Journal of Clinical Investigation, Vol. 76, Issue 2 https://doi.org/10.1172/JCI112000	journal	August 1985
PKC Signaling Regulates Drug Resistance of the Fungal Pathogen Candida albicans via Circuitry Comprised of Mkc1, Calcineurin, and Hsp90 LaFayette, Shantelle L.; Collins, Cathy; Zaas, Aimee K. PLoS Pathogens, Vol. 6, Issue 8 https://doi.org/10.1371/journal.ppat.1001069	journal	August 2010
Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance Brian Houston, J. Biochemical Pharmacology, Vol. 47, Issue 9 https://doi.org/10.1016/0006-2952(94)90520-7	journal	April 1994
Scaling Factors for the Extrapolation of In Vivo Metabolic Drug Clearance From In Vitro Data: Reaching a Consensus on Values of Human Micro-somal Protein and Hepatocellularity Per Gram of Liver Barter, Zoe; Bayliss, Martin; Beaune, Philip Current Drug Metabolism, Vol. 8, Issue 1 https://doi.org/10.2174/138920007779315053	journal	January 2007
XDS Kabsch, Wolfgang Acta Crystallographica Section D Biological Crystallography, Vol. 66, Issue 2 https://doi.org/10.1107/S0907444909047337	journal	January 2010
Overview of the CCP 4 suite and current developments Winn, Martyn D.; Ballard, Charles C.; Cowtan, Kevin D. Acta Crystallographica Section D Biological Crystallography, Vol. 67, Issue 4 https://doi.org/10.1107/S0907444910045749	journal	March 2011
Features and development of Coot Emsley, P.; Lohkamp, B.; Scott, W. G. Acta Crystallographica Section D Biological Crystallography, Vol. 66, Issue 4 https://doi.org/10.1107/S0907444910007493	journal	March 2010
Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix Liebschner, Dorothee; Afonine, Pavel V.; Baker, Matthew L. Acta Crystallographica Section D Structural Biology, Vol. 75, Issue 10 https://doi.org/10.1107/S2059798319011471	journal	October 2019
Collaboration gets the most out of software Morin, Andrew; Eisenbraun, Ben; Key, Jason eLife, Vol. 2 https://doi.org/10.7554/eLife.01456	journal	September 2013

Similar Records

Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors: Optimization of Whole-Cell Anticryptoco

Journal Article · 2021 · J. Med. Chem. · OSTI ID:1834912

Marcyk, Paul T.; LeBlanc, Emmanuelle V.; Kuntz, Douglas A.; +13 more

Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors: Optimization of Whole-Cell Anticryptoco

Journal Article · 2021 · J. Med. Chem. · OSTI ID:1832573

Marcyk, Paul T.; LeBlanc, Emmanuelle V.; Kuntz, Douglas A.; +13 more

Whole Cell Active Inhibitors of Mycobacterial Lipoamide Dehydrogenase Afford Selectivity over the Hu

Journal Article · 2021 · ACS Infect. Dis. · OSTI ID:1828912

Ginn, John; Jiang, Xiuju; Sun, Shan; +17 more

Related Subjects

99 GENERAL AND MISCELLANEOUS

Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors: Optimization of Whole-Cell Anticryptococcal Activity and Insights into the Structural Origins of Cryptococcal Selectivity

Citation Formats

References (86)

Similar Records

Related Subjects